multiple myeloma/albumin

Serum albumin level, in association with serum interleukin-6 level, is a significant prognostic factor in multiple myeloma patients. The aim of this study was to determine any clinical factors associated with decreased serum albumin level. We retrospectively reviewed the records of 373 patients

Renal failure is a common morbidity in multiple myeloma (MM). Although proteinuria has been increasingly reported in malignancies, it is not routinely used to refine risk estimates of survival outcomes in patients with MM. Here we aimed to investigate initial serum albumin and 24-hour daily protein

Multiple myeloma (MM) is a heterogeneous disease group regarding prognosis, clinical course, and response to therapeutic interventions. Numerous prognostic factors have been identified however there was no consensus about the best prognostic indicators or the proper staging systems. In a previous

BACKGROUND The International Staging System for multiple myeloma has increased the importance of accurate measurement of serum albumin. Two common albumin assays, bromcresol green (BCG) and agarose gel protein electrophoresis (PEL), frequently yield discordant results, creating confusion regarding

OBJECTIVE Since the prognostic significance of the combination of beta-2-microglobulin (beta(2)m) and albumin in multiple myeloma (MM) has been recognized, these two easily obtainable parameters were subsequently employed in the staging systems of Bataille et al. (BSS), the South West Oncology Group

In 71 patients with multiple myeloma the authors evaluated the clinical significance and the prognostic relevance of Bataille's stratification system based on serum beta 2-microglobulin and serum albumin levels. This staging system, which classified the patients to low, intermediate and poor risk

Multiple myeloma, a hematological malignancy typified by the clonal expansion of bone marrow plasma cells, contributes to one percent of all malignancies worldwide. Despite myeloma only contributing to 10% of all hematological malignancies, it carries significant morbidity owing to its heterogenous

Background: Acute kidney injury (AKI) occurs in 12-20% of multiple myeloma (MM) patients. Several studies have shown a reduction of free light chains (FLC) using hemodialysis with High-Cut-Off membranes. However, this technique entails

The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity. However, recent data

Sera from a pool of 800 healthy donors and from 3 individual healthy donors were passed through tubulin, actin, thyroglobulin, myoglobin, fetuin, transferrin and albumin immunoadsorbents. Proteins were eluted in all the immunosorbents and were found to be essentially composed of the three major Ig